Alemtuzumab IV — disease-defining anti-CD52, 12 weeks induction
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ALEMTUZUMAB |
|---|
| ID | REG-ALEMTUZUMAB-IV |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
STUB. SC alemtuzumab is less effective for T-PLL — IV preferred. Severe pan-lymphopenia → opportunistic infection prophylaxis is mandatory ≥6 months after the last dose. Allo-SCT planning immediately after CR.
Used By
Contraindications
CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB- CI-ACTIVE-INFECTION-FOR-ALEMTUZUMAB
Indication
IND-T-PLL-1L-ALEMTUZUMAB- IND-T-PLL-1L-ALEMTUZUMAB
Supportive Care
SUP-CMV-MONITORING- CMV PCR surveillance during T-cell-depleting therapy